Continuing-ops NPAT +13% but statutory PBT swung to a $3.0m loss

What changed

Reported revenue fell 9.7% to $47.6m from $52.7m, but that reflects the loss of the divested ANZ business. On a continuing-operations basis, revenue rose 11.2% (to $47.6m from $42.8m) and continuing-ops NPAT rose 13.3% to $1.7m from $1.5m. Statutory PBT swung from a $2.6m profit to a $3.0m loss, and headline NPAT fell 46.9% to $1.7m – the gap between PBT and NPAT reflects a $4.7m tax benefit against the pre-tax loss (implied effective tax rate of 157%), so NPAT is tax-distorted.

Operating cash flow fell 24.2% to $7.5m, capex was broadly flat at $4.6m, and pre-lease free cash flow compressed to $2.9m from $5.2m. Despite that, cash rose to $15.2m from $6.2m and gross borrowings fell to $26.7m from $33.6m, cutting net debt to $11.5m from $27.4m. No dividend was declared.

What matters

• Continuing-operations improvement is the real read. Continuing revenue +11.2% and continuing NPAT +13.3% is a cleaner signal than the headline numbers, which are dragged down by lapping last year's ANZ contribution. The statutory PBT loss still shows the business is not comfortably profitable on a fully-loaded basis.
• Balance-sheet repair is the most concrete positive. Net debt roughly halved and inventory was drawn down by $7.2m (inventory days improved from 463 to 334). Leverage direction is materially strengthening even though net-debt-to-EBITDA is not computable without a disclosed FY22 EBITDA figure.
• Cash conversion weakened. OCF fell $2.4m despite working-capital release from inventory, and pre-lease FCF fell 44%. That is a notable deterioration alongside the reported trade-receivables movement, and it tempers the otherwise strong cash balance (which likely reflects divestment proceeds rather than trading conversion).

Expectations

Management had re-confirmed FY22 US GAAP EBITDA guidance in a range of US$11.3m–US$11.7m. FY22 EBITDA itself is not disclosed in the supplied extracts, so whether the year landed inside that range cannot be verified here. HY22 context confirms the business is extremely second-half-weighted (H1 revenue was only ~9.7% of the full year, H1 NPAT ~5.9% of the full year), which is consistent with the disclosed cone/seed cycle and means interim prints should not be linearly extrapolated. No forward-work or FY23 target was supplied.

Quality of result

Quality is mixed. The underlying continuing-operations growth rate is genuine but modest in dollar terms ($4.8m revenue uplift, $0.2m NPAT uplift). The bottom-line NPAT is materially tax-assisted: without the $4.7m tax credit, the loss before tax would be the cleaner trend read, and that swung negative. Working-capital release (inventory down $7.2m) supported cash generation and inventory-days normalisation, but is by definition not repeatable at the same magnitude. Cash conversion relative to earnings deteriorated, and the large cash build likely owes more to ANZ divestment proceeds and debt paydown dynamics than to operating momentum. FX translation also had a visible effect on cash.

Unresolved

• FY22 US GAAP EBITDA is not in the supplied excerpts, so whether the reconfirmed US$11.3m–US$11.7m guidance was met is not established.
• No reconciliation from statutory PBT to the US GAAP EBITDA measure was disclosed, leaving the non-GAAP bridge opaque.
• The composition of the $4.7m tax benefit (deferred tax recognition, prior-period true-ups, or divestment-related) is not explained.
• No FY22 segment split or customer/geographic concentration was provided, despite narrative emphasis on US MCP growth and Brazil.
• No dividend policy or capital-allocation statement accompanied the stronger cash position.

This briefing cannot assess whether the headline US GAAP EBITDA guidance was met, nor the unit economics of the US MCP growth story, because those disclosures are not present in the supplied data.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.